Are Longevity Clinics Worth It?

The blunt answer

Direct-to-consumer and concierge "longevity clinics" — the ones selling IV drips, NAD+ infusions, peptide stacks, and "optimization" panels — sit on the weakest evidence in the entire longevity field. Some offer genuinely useful, evidence-based care. Many sell mechanistically plausible interventions at premium prices with little human proof. The difference is worth thousands of dollars and your trust. For the full evidence map, see longevity medicine: what's proven vs hyped.

What the evidence actually says about IV "longevity therapy"

The clearest assessment comes from a critical review of the IV "longevity therapy" offerings common at these clinics — high-dose vitamins, glutathione, NAD+ infusions, and similar drips. Its conclusions are unflattering: the supporting evidence comes mostly from disease-specific or aesthetic contexts rather than longevity, placebo-controlled trials are scarce, underpowered, and conflicting, and validated aging biomarkers are rarely even measured¹.

In plain terms: much of what IV longevity clinics sell has never been tested for the purpose they sell it for, and they often don't measure whether it worked using any validated marker of aging.

Why this happens

The business model rewards the appearance of cutting-edge science. NAD+ infusions sound advanced; a glutathione drip feels like biohacking. But "raises a lab value" is not the same as "improves your health," and the gap between the two is exactly where the marketing lives. A clinic can truthfully say your NAD+ went up while having no evidence that anything you care about changed.

This is compounded by the field's overall immaturity. The methodology for running human trials that actually demonstrate extended healthspan is still being developed, which means clinics are operating well ahead of the evidence that would justify their claims². That is not automatically dishonest — but it puts the burden on you to vet carefully.

It also makes a certain kind of marketing very easy. When the validated outcome measures don't yet exist, a clinic can sell almost any intervention as "longevity" and point to a rising lab value or a mechanistic rationale rather than a result. The absence of agreed-upon endpoints isn't a gap the clinic is heroically filling; it's the reason the claims can't be checked. Treat "we're at the cutting edge, the trials are still coming" as a reason for more scrutiny, not less — and remember that paying to be an early adopter of an unproven intervention is a choice you should make with eyes open, not one a glossy clinic should make feel inevitable.

How to vet a longevity clinic

A worthwhile provider behaves differently from a drip-bar. Look for these signals:

- **They distinguish proven from plausible.** A good clinic tells you GLP-1 drugs have hard cardiovascular-outcome data while NAD+, rapamycin, and metformin do not. If everything is pitched as equally "proven," walk. - **They cite human RCTs, not mouse studies or in-house testimonials.** Animal lifespan data is interesting context, not a reason to pay. - **They measure validated outcomes.** Standard cardiometabolic markers and clinically meaningful endpoints beat vague "longevity panels" full of unvalidated biomarkers. - **They are honest about risk.** Any clinic marketing growth hormone or GH-secretagogue peptides as anti-aging is ignoring the evidence — that is a red flag, not a feature. - **They avoid the endpoint switch.** Be wary when "your NAD+ rose" or "your IGF-1 increased" is presented as the result. Ask what outcome you'd actually feel or benefit from, and whether it was measured. - **Pricing matches evidence.** Premium prices for interventions with no human outcome data should give you pause.

So — worth it?

It depends entirely on the clinic. A provider that uses evidence-based tools honestly, measures validated outcomes, and is candid about what's unproven can be worth it, especially for legitimately supported interventions. A clinic built around IV drips and unmeasured "optimization" is selling hope at a markup. The critical-review evidence puts the default skepticism squarely on the IV-and-infusion end of the market¹.

For our independently graded shortlist of providers that pass the tests above, see our longevity clinic rankings. And before you go, read the underlying evidence on NAD+ and peptides and rapamycin & metformin so you can hold any clinic to it.